SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

Heat-shock protein 90 (Hsp90) acts as a molecular chaperone required for maintaining the conformational stability of client proteins regulating cell proliferation, survival, and apoptosis. Here we investigate the biologic significance of Hsp90 inhibition in multiple myeloma (MM) and other hematologic tumors using an orally available novel small molecule inhibitor SNX-2112, which exhibits unique activities relative to 17-allyamino-17-demethoxy-geldanamycin (17-AAG). SNX-2112 triggers growth inhibition and is more potent than 17-AAG against MM and other malignancies. It induces apoptosis via caspase-8, -9, -3, and poly (ADP-ribose) polymerase cleavage. SNX-2112 inhibits cytokine-induced Akt and extracellular signal-related kinase (ERK) activation and also overcomes the growth advantages conferred by interleukin-6, insulin-like growth factor-1, and bone marrow stromal cells. Importantly, SNX-2112 inhibits tube formation by human umbilical vein endothelial cells via abrogation of eNOS/Akt pathway and markedly inhibits osteoclast formation via down-regulation of ERK/c-fos and PU.1. Finally, SNX-2112, delivered by its prodrug SNX-5422, inhibits MM cell growth and prolongs survival in a xenograft murine model. Our results indicate that blockade of Hsp90 by SNX-2112 not only inhibits MM cell growth but also acts in the bone marrow microenvironment to block angiogenesis and osteoclastogenesis. Taken together, our data provide the framework for clinical studies of SNX-2112 to improve patient outcome in MM and other hematologic malignancies.

[1]  E. Zuhowski,et al.  Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers , 2005, Clinical Cancer Research.

[2]  T. Libermann,et al.  Antimyeloma activity of heat shock protein-90 inhibition. , 2005, Blood.

[3]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[4]  F. B. Dunn.  Heat shock protein inhibitor shows antitumor activity. , 2002, Journal of the National Cancer Institute.

[5]  J. D. Vos,et al.  Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1 , 2000, Cell Death and Differentiation.

[6]  Roger Fan,et al.  Dynamic activation of endothelial nitric oxide synthase by Hsp90 , 1998, Nature.

[7]  N. Munshi,et al.  Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). , 2006, Blood.

[8]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[9]  R. Kyle,et al.  Multiple myeloma. , 2008, Blood.

[10]  Rey-Huei Chen,et al.  Molecular interpretation of ERK signal duration by immediate early gene products , 2002, Nature Cell Biology.

[11]  Sarat Chandarlapaty,et al.  SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers , 2008, Clinical Cancer Research.

[12]  Mone Zaidi,et al.  Osteoclast signalling pathways. , 2005, Biochemical and biophysical research communications.

[13]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[14]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[15]  E. Wagner,et al.  Bone and haematopoietic defects in mice lacking c-fos , 1992, Nature.

[16]  D. Chauhan,et al.  Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.

[17]  L. Neckers,et al.  Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update , 2005, Expert opinion on emerging drugs.

[18]  Satoru Takahashi,et al.  Synergistic Activation of Endothelial Nitric-oxide Synthase (eNOS) by HSP90 and Akt , 2003, Journal of Biological Chemistry.

[19]  L. Grochow,et al.  Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Libermann,et al.  Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. , 2004, Cancer cell.

[21]  W. Dalton,et al.  Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines , 1999 .

[22]  A. Harris,et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.

[23]  P. Richardson,et al.  An update of novel therapeutic approaches for multiple myeloma , 2004, Current treatment options in oncology.

[24]  L. Pearl,et al.  Structure and mechanism of the Hsp90 molecular chaperone machinery. , 2006, Annual review of biochemistry.

[25]  N. Munshi,et al.  Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. , 2002, Molecular cancer therapeutics.

[26]  A. Zallone,et al.  c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. , 2003, The Journal of clinical investigation.

[27]  Masaharu Akiyama,et al.  Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications , 2002, Oncogene.

[28]  G. Roodman.  Pathogenesis of myeloma bone disease , 2009, Journal of cellular biochemistry.

[29]  K. Anderson,et al.  Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Hong Zhang,et al.  Hsp90 Activation and Cell Cycle Regulation , 2004, Cell cycle.

[31]  Marina Ziche,et al.  Nitric Oxide and Angiogenesis , 2000, Journal of Neuro-Oncology.

[32]  C. Fegan,et al.  The clinical outcome and toxicity of high‐dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study , 2006, British journal of haematology.

[33]  V. Palombella,et al.  IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells , 2008, Cancer Chemotherapy and Pharmacology.

[34]  J. Liao,et al.  Induction of Angiogenesis by Heat Shock Protein 90 Mediated by Protein Kinase Akt and Endothelial Nitric Oxide Synthase , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[35]  K. Anderson,et al.  Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts) , 2007 .

[36]  T G Myers,et al.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.

[37]  Hong Zhang,et al.  Targeting multiple signal transduction pathways through inhibition of Hsp90 , 2004, Journal of Molecular Medicine.

[38]  G. Roodman.  Erratum to ?Pathogenesis of myeloma bone disease? 6Blood Cells Mol. Dis. 32 (2004) 290?2929 , 2004 .

[39]  Satoru Takahashi,et al.  Calmodulin-dependent and -independent Activation of Endothelial Nitric-oxide Synthase by Heat Shock Protein 90* , 2003, The Journal of Biological Chemistry.

[40]  C. Cordon-Cardo,et al.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  G Muller,et al.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.

[42]  P. Steeg,et al.  Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. , 2006, Chemical research in toxicology.

[43]  S. Rajkumar,et al.  Angiogenesis in multiple myeloma , 2001, British journal of haematology.

[44]  E. Sausville,et al.  Clinical development of 17-allylamino, 17-demethoxygeldanamycin. , 2003, Current cancer drug targets.

[45]  G. Georgakis,et al.  Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. , 2005, Future oncology.

[46]  S. Mckercher,et al.  Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 , 1997, Nature.

[47]  D. Ribatti,et al.  Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. , 1999, Blood.

[48]  T. Hideshima,et al.  Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma , 2006, Clinical Cancer Research.

[49]  P. Fadden,et al.  545 POSTER SNX-2112: a novel, selective, potent small molecule inhibitor of Hsp90 with unique pharmacodynamic properties , 2006 .

[50]  Richard Dahl,et al.  Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPα ratio and granulocyte colony-stimulating factor , 2003, Nature Immunology.

[51]  P. Richardson,et al.  Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma , 2005, British journal of haematology.

[52]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[53]  c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation , 2003 .